Genentech's Columvi label expansion gets negative vote by FDA committee

 Genentech's FDA advisory setback: Columvi combo for relapsed diffuse large B-cell lymphoma faces approval hurdle.

https://seekingalpha.com/news/4450620-genentechs-columvi-label-expansion-gets-negative-vote-by-fda-committee